Journal
SCIENTIFIC REPORTS
Volume 6, Issue -, Pages -Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/srep37436
Keywords
-
Categories
Funding
- LABEX (excellence laboratory, program investment for the future) DistALZ (Development of Innovative Strategies for a Transdisciplinary approach to ALZheimer's disease)
- Hospital University federation (FHU) OncoAge
- DistALZ
- CNRS, INSERM
- Conseil Departemental des Alpes Maritimes
- Fondation Claude Pompidou
Ask authors/readers for more resources
The aspartyl protease beta-site APP cleaving enzyme, BACE1, is the rate-limiting enzyme involved in the production of amyloid-beta peptide, which accumulates in both sporadic and familial cases of Alzheimer's disease and is at the center of gravity of the amyloid cascade hypothesis. In this context, unravelling the molecular mechanisms controlling BACE1 expression and activity in both physiological and pathological conditions remains of major importance. We previously demonstrated that A beta controlled BACE1 transcription in an NF kappa B-dependent manner. Here, we delineate an additional cellular pathway by which natural and synthetic A beta 42 oligomers enhance active X-box binding protein XBP-1s. XBP-1s lowers BACE1 expression and activity indirectly, via the up-regulation of the ubiquitin-ligase HRD1 that acts as an endogenous down-regulator of BACE1. Thus, we delineate a novel pathway by which cells could compensate for A beta 42 oligomers production and thus, associated toxicity, by triggering a compensatory mechanism aimed at lowering BACE-1-mediated A beta production by a molecular cascade involving XBP-1s and HRD1. It thus identifies HRD1 as a potential target for a novel A beta-centered therapeutic strategy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available